

ATONCO ANNOUNCES THE APPOINTMENT OF ADRIEN REYMOND AS DIRECTOR OF RA/QA

Atonco announced today that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead Regulatory Affairs and Quality.

Adrien, with 15 years of experience in the radiopharmaceutical industry (AAA, a Novartis company), PETNET Solutions (a Siemens company), Atlanpole Biotherapies and consulting for innovative radiopharmaceutical companies will be in charge of pharmaceutical affairs, regulatory affairs and quality assurance to be in compliance with Good Clinical Practices (GCP) and preparation of the ISO 9001:2015 certification

The entire Atonco team is delighted to welcome Adrien Reymond to the company, both for his expertise and experience in the radiopharmaceutical industry and for his motivation to join the Atonco adventure.

About ATONCO

ATONCO is a privately held French company developing molecularly targeted radiopharmaceuticals for oncology applications. Originating from the world-class nuclear medicine cluster in Nantes, ATONCO and its academic partners are committed to the clinical use of alpha-emitting radionuclides, in particular astatine-211 (²¹¹At).

For more information, visit www.atonco-pharma.com

Important Information This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available